lacosamide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 59 Diseases   24 Trials   24 Trials   1996 News 


«12345678910111213...2526»
  • ||||||||||  Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
    Journal:  Antiseizure medication-induced hypersensitivity reactions: Data from a large healthcare system. (Pubmed Central) -  Nov 6, 2024   
    Our data reveals important patterns in HR to ASMs that may be valuable to clinicians treating PWE. Clinicians should monitor closely for HR when beginning a new ASM in a patient who has taken an aromatic ASM, especially carbamazepine, oxcarbazepine, or eslicarbazepine as well as phenobarbital.
  • ||||||||||  lacosamide / Generic mfg.
    Safety and Tolerability of High-Dose Intravenous Push Lacosamide (Grand Hall) -  Oct 17, 2024 - Abstract #NCS2024NCS_151;    
    Conclusion Intravenous push administration of undiluted LCM 400 mg was well tolerated and led to significantly faster administration. Further prospective research is needed to confirm these observations.
  • ||||||||||  lacosamide / Generic mfg.
    Lacosamide-Induced Thrombotic Microangiopathy () -  Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_4969;    
    DITMA can sometimes be challenging to diagnose, especially in the ICU setting. Although literature on lacosamide induced TMA is scarce, this case sheds the importance of keeping TMA as a differential in the setting of new onset thrombocytopenia and anemia after starting new medications..
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma
    Journal:  Comparative safety analysis of lacosamide and perampanel in epilepsy management: insights from FAERS database. (Pubmed Central) -  Oct 4, 2024   
    This comprehensive evaluation underscores the importance of understanding the distinct AE profiles of LCM and PER in clinical practice, providing valuable insights for personalized epilepsy management. Future research with rigorous prospective designs is recommended to validate these findings and explore the mechanisms underlying the reported adverse events.
  • ||||||||||  lacosamide / Generic mfg., phenytoin / Generic mfg., levetiracetam / Generic mfg.
    Review, Journal:  Subacute encephalopathy with seizures in alcoholics (SESA) syndrome: Relevant questions. (Pubmed Central) -  Sep 11, 2024   
    SESA syndrome represents a well-defined subtype of focal NCSE in patients with chronic alcoholism. Its prompt recognition can facilitate the initiation of early ASM therapy and help design appropriate video-EEG evaluation and a treatment strategy.
  • ||||||||||  levetiracetam / Generic mfg.
    KEPPRA-INDUCED RHABDODMYOLYSIS (Convention Center Exhibit Hall: Poster Area 2) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6379;    
    This report emphasizes the necessity of monitoring CPK levels during the initiation or reintroduction of levetiracetam for patients, as rhabdomyolysis remains a potential complication. Additionally, it underscores that even if patients have previously tolerated the medication, the occurrence of rhabdomyolysis cannot be ruled out, and it should be considered as one of the differentials in clinical evaluation.
  • ||||||||||  lacosamide / Generic mfg., levetiracetam / Generic mfg., clobazam / Generic mfg.
    RECURRENT METABOLIC ENCEPHALOPATHY IN AN ADULT WITH ANGELMAN SYNDROME, LENNOX-GASTAUT SYNDROME, AND VLCAD DEFICIENCY: WHEN REMEDY FOR ONE MALADY IS THE CATALYST FOR ANOTHER (Convention Center Exhibit Hall: Poster Area 2) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6377;    
    Diagnosis is based on specific patterns of acylcarnitine elevation.(4) CASE PRESENTATION: The 38-year-old male, with Angelman syndrome related seizures treated with valproate, levetiracetam, levocarnitine, presented due to increased seizure frequency and myoclonic jerks...Clobazam and lacosamide reduced seizures initially, but lethargy developed post-discharge... Establishing the cause of metabolic encephalopathy in patients with complex syndromic pathology is essential to improve prognosis alongside empiric management.
  • ||||||||||  Review, Journal:  Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers. (Pubmed Central) -  Sep 8, 2024   
    We conclude that there is strong variance in the pharmacological effects of these drugs, and in the available information. At present, GS967 and riluzole can be regarded bona fide INaP blockers, while phenytoin and lacosamide are blockers that only act on the slowly inactivating component of sodium currents.
  • ||||||||||  Subtype selectivity of clinically-used sodium channel inhibitors (MCP Hall A) -  Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_12238;    
    The likely explanation is likely two-fold: first, cardiac atrial and ventricular muscle has much more negative resting potential (near -88 mV) than most neurons (typically -85 to -60 mV), so that a larger fraction of channels are in the resting state with weak drug binding, and second, cardiac muscle cells have a high density of sodium channels, so that inhibition of a substantial fraction of sodium channels can be tolerated with minimal functional consequences. The strong state-dependence of drug action also likely accounts for functional selectivity of drug on neurons to inhibit pathophysiological conditions like pain and epilepsy without major disruption of normal functions.
  • ||||||||||  lacosamide / Generic mfg.
    Different Coding Mechanisms In Humans For Evoked Pain Stimuli Versus Spontaneous Neuropathic Pain (MCP Hall A) -  Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_4252;    
    The strong state-dependence of drug action also likely accounts for functional selectivity of drug on neurons to inhibit pathophysiological conditions like pain and epilepsy without major disruption of normal functions. Off-label treatment with the sodium channel modulator lacosamide alleviated pain only in SFN1 with a parallel decrease in SA and a more normal heat pain threshold of 48.5
  • ||||||||||  lacosamide / Generic mfg.
    Journal:  Unusual adult-onset cardiac rhabdomyomas in tuberous sclerosis complex: a case report. (Pubmed Central) -  Aug 15, 2024   
    A 22-year-old male patient of Afro-descendant, diagnosed with tuberous sclerosis complex in childhood, presented with refractory epilepsy and was treated only with lacosamide...These late-onset cases can exhibit various symptoms, from simple to complex presentations. Regular clinical checkups are essential for adults with tuberous sclerosis complex.
  • ||||||||||  lacosamide / Generic mfg., phenytoin / Generic mfg., levetiracetam / Generic mfg.
    Review, Journal:  Subacute encephalopathy with seizures in alcoholics (SESA) syndrome. (Pubmed Central) -  Aug 10, 2024   
    SESA syndrome represents a well-defined subtype of focal NCSE in patients with chronic alcoholism. Its prompt recognition can facilitate the initiation of early ASM therapy and help implement a video-EEG evaluation and neuroimaging strategy.
  • ||||||||||  lacosamide / Generic mfg., phenobarbital / Generic mfg., levetiracetam / Generic mfg.
    Management of Severe Neonatal Seizures in a Patient with KARS1 Variant (Exhibit Hall) -  Aug 6, 2024 - Abstract #ASA2024ASA_5009;    
    Eventually, the seizures subsided with a serum phenobarbital level of 80 mcg/ml. Multiple anti-seizure medications were weaned and the patient discharged on maintenance lacosamide, levetiracetam and phenobarbital.
  • ||||||||||  Journal:  Endoscope-Assisted Evacuation of an Acute Subdural Hematoma in an Elderly Patient With Refractory Nonconvulsive Status Epilepticus: An Illustrative Case. (Pubmed Central) -  Aug 5, 2024   
    The initial treatment was conservative, including the administration of lacosamide at 100 mg/day...Although the convulsions stopped after the administration of diazepam 10 mg IV and her consciousness temporarily improved, it worsened again on day 6, leading to a diagnosis of NCSE on an electroencephalogram (EEG). Despite aggressive pharmacological interventions with fosphenytoin (750 mg initially followed by 262 mg/day) and phenobarbital (625 mg/day), the patient's cognitive state and EEG findings did not improve...This case demonstrates that even the absence of a significant mass effect from ASDH
  • ||||||||||  Xcopri (cenobamate) / SK Bio, Nayzilam (midazolam intranasal) / UCB
    VAGAL NERVE STIMULATOR-INDUCED SLEEP DISORDERED BREATHING IN A PATIENT WITH REFRACTORY SEIZURES (Convention Center Exhibit Hall: Poster Area 5) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_5654;    
    This case report elucidates several novel aspects, informed by the provided data. VNS benefits in patients with refractory seizures but careful observation and monitoring is recommended with any patients with preexisting sleep disordered breathing.
  • ||||||||||  Clinical, Journal:  Comparison Table: Some oral antiseizure medications. (Pubmed Central) -  Jul 29, 2024   
    VNS benefits in patients with refractory seizures but careful observation and monitoring is recommended with any patients with preexisting sleep disordered breathing. No abstract available
  • ||||||||||  Review, Journal:  Drugs for epilepsy. (Pubmed Central) -  Jul 29, 2024   
    No abstract available No abstract available
  • ||||||||||  lacosamide / Generic mfg.
    Journal:  Intravenous Lacosamide Therapy for Pediatric Patients With Cluster Seizures. (Pubmed Central) -  Jul 18, 2024   
    Randomized controlled studies are needed to establish its effectiveness and adequate dosing regimen in this population. Intravenous lacosamide therapy is a potentially useful treatment option for cluster seizures in pediatric patients.
  • ||||||||||  SUCCESSFUL MANAGEMENT OF TOTAL PAIN FOR A LADY WITH ASTROCYTOMA. (Exhibition Hall/Poster Area) -  Jul 18, 2024 - Abstract #IASP2024IASP_1670;    
    She tolerates her anti-epileptic therapy which also covers now the behavioural and vegetative aspects. The frontal headaches most likely represented her total pain represented initially by the raised intracranial pressure and poor prognosis.
  • ||||||||||  Nucynta (tapentadol) / Collegium Pharma, Grunenthal
    Evaluating the Impact of Lacosamide, Pregabalin, and Tapentadol on Spinal Biomarkers in Human Subjec (Exhibition Hall/Poster Area) -  Jul 18, 2024 - Abstract #IASP2024IASP_809;    
    This experimental design failed to identify a significant effect of tapentadol on the N13. Pregabalin seems to have the same efficacy as tapentadol in preventing changes in spinal excitability, proving to have an antihyperalgesic effect, detectable with the use of the nociceptive flexion reflex.
  • ||||||||||  lacosamide / Generic mfg.
    Clinical, Journal:  Intravenous push lacosamide: Successful implementation and patient outcomes across a health system. (Pubmed Central) -  Jul 17, 2024   
    However, the certainty of almost all comparisons was "very low", and careful interpretation is essential. Transitioning intravenous lacosamide administration from piggyback to push administration is feasible and decreases time from verification to administration without increased incidence of adverse effects.
  • ||||||||||  lacosamide / Generic mfg., mirtazapine / Generic mfg.
    Biomarker, Clinical, Observational data, Preclinical, Retrospective data, Review, Journal:  A case of lacosamide and mirtazapine self-poisoning. (Pubmed Central) -  Jul 15, 2024   
    The synergistically central nervous system depressive and cardiotoxic effects of these drugs may have contributed to the cause of death. We concluded that the cause of death in this case was lacosamide and mirtazapine poisoning.
  • ||||||||||  Fycompa (perampanel) / Eisai, Catalyst Pharma
    Journal:  Serum perampanel levels in patients with seizures are not affected by hemodialysis. (Pubmed Central) -  Jun 26, 2024   
    In 14 patients who started treatment between April 2020 and March 2023, perampanel serum levels did not decrease during hemodialysis, unlike other seizure medications. This shows that perampanel can be a good option for patients with seizures who need hemodialysis, with fewer side effects compared to other medications.